EX-10.51



 Exhibit 10.51 

Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “***” and has been filed separately with the Securities and
Exchange Commission pursuant to a Confidential Treatment Application with the Commission. 
  
 



 
 OMB Approval 2700-0012 
1. CONTRACT ID CODE

PAGE OF PAGES 
AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 
1 2 
2. AMENDMENT/MODIFICATION NO. 
3. EFFECTIVE DATE 
4. REQUISITION/PURCHASE REQ. NO. 
5. PROJECT NO. (If applicable) 
One (1) 
See block #16C 
3228551 
6. ISSUED BY 
CODE 
7. ADMINISTERED BY (If other than Item 6) 
CODE 
N/A 
National Institutes of Health 
National Institute of Allergy and Infectious Diseases 
DEA, Office of Acquisitions 
Room 3214, MSC 7612 
6700-B Rockledge Drive 
Bethesda, MD 20892-7612 
MID RCB-A 
B. NAME AND ADDRESS OF CONTRACTOR (No. Street, county. State and ZIP: Code) (4) 
9A. AMENDMENT
OF SOLICITATION NO. 
BIOCRYST PHARMACEUTICALS, INC. 4505 EMPEROR BLVD SUITE 200 DURHAM, NC 27703 
9B. DATED (SEE ITEM 11) X 
10A. MODIFICATION OF CONTRACT/ORDER NO. 
HHSN272201300017C 
10B. DATED (SEE ITEM 13) 
CODE 
FACILITY CODE 
September 16, 2013 
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS 
The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers is extended, is not extended. Offers must acknowledge
receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods: 
(a) By completing Items 8 and
15, and returning one (1) copy of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment
numbers, FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATA SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already
submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and data specified. 
12. ACCOUNTING AND APPROPRIATION DATA (If required) 
SOC 25.55 Can 14-8470038 $2,502,146

13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS, IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14. 
A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A. 
B. THE ABOVE NUMBERED CONTRACT/ORDER. IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN 
ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b). 
C. THIS SUPPLEMENTAL AGREEMENT IS
ENTERED INTO PURSUANT TO AUTHORITY OF: 
D. OTHER Specify type of modification and authority) 
X FAR 52.217-7 
E. IMPORTANT: Contractor is not, is required to sign this document and return
copies to the issuing office. 
14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where
feasible.) 
PURPOSE: To execute option 3. 
The completion date of the contract
is not changed to September 15, 2017. Total cost is changed to $7,502,146 
Except as provided herein, all terms and conditions of the document referenced in
Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect. 
15A. NAME AND TITLE OF SIGNER (Type or print) 
16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print) 
Jon P. Stonehouse CEO 
John Outen, Contracting Officer 
Office of Acquisitions, DEA, NIAID, NIH DHHS 
15B. CONTRACTOR/OFFEROR 
15C. DATE SIGNED 
16B. UNITED STATES OF AMERICA 
16C. DATE SIGNED 
(Signature of person authorized to sign) 
12/26/13 
(Signature of Contracting Officer) 
12/24/2013 
NSN 7540-01-152-8070 PREVIOUS EDITION UNUSABLE 
30-105 Computer Generated 
STANDARD FORM 30 (REV. 10-83) 
Proscribed by GSA FAR (48 CFR) 53.243 







 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “***” and has
been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application with the Commission. 
  

					
	SPECIAL PROVISIONS	  	Contract No. HHSN272201300017C	  	Page 2 of 2
		  	Modification No. 1	  	
		  		  	

 Beginning with the effective date of this modification. ARTICLE B.2. ESTIMATED COST – OPTION AND ARTICLE G.3
INVOICE SUBMISSION /CONTRACT FINANCING REQUEST IS REVISED 
 ARTICLE B.2. ESTIMATED COST – OPTION is revised to incorporate changes and
add paragraph e with the Option table below: 
  

	 	a.	The estimated cost of this contract is $ *** with the execution of Option 3. 

  

	 	b.	The fixed fee for this contract is $*** for the Base and all executed options. The fixed fee shall be paid in installments based on the percentage of completion of work, as determined by the Contracting Officer. Payment
shall be subject to the withholding provisions of the clauses ALLOWABLE COST AND PAYMENT and FIXED FEE referenced in the General Clause Listing in Part II, ARTICLE I.1. of this contract. 


 

	 	c.	The total estimated amount of the contract, represented by the sum of the estimated cost plus the fixed fee for the Base Period and all options is $7,502,146 


e. Payments from the base and executed options will be made from the following PRISM/NBS Line Item Numbers as follows: 

 

									
	 PRISM/NBS
Line Item No.
	  	 Option/Increment Description
	  	 PRISM/NBS Line Item

Period of Performance
	  	Funded Amount	 
	 1

(BASE)
	  	 Base Period: Non-GMP manufacture of drug substance, drug disposition, genetic toxicity and in vitro and small animal efficacy
studies
	  	09/16/2013 - 09/15/2014	  	$	 ***	  
	 2

(Option 1)
	  	 Option 1-Manufacture of drug substance and drug product in compliance with cGMP guidance - GMP
	  	09/16/2013 - 09/27/2014	  	$	***	  
	 3

(Option 2)
	  	 Option 2-DP and Development with DS Stability testing
	  	09/16/2013 - 09/15/2017	  	$	***	  
	 4

(Option 3
 MOD 1)
	  	 Option 3-IM IND-Enablement and Submission
	  	12/24/2013 - 12/23/2014	  	$	2,506,042	  

 END OF MODIFICATION 1 OF HHSN272201300017C